Predictive Oncology FY2023 revenue $1.78M, net loss $14M, EPS -$3.48

Axe Compute Inc.

Net loss of ~$14M on total revenue of ~$1.8M for year ended Dec 31, 2023.
Basic and diluted EPS improved 50% YoY to -$3.48 from -$6.98.
Cash and cash equivalents $8.7M at Dec 31, 2023, down from $22.1M at Dec 31, 2022.
Collaboration progress: FluGen intranasal flu vaccine, Cancer Research Horizons glutaminase inhibitors, UPMC ovarian cancer AI study.
Q4 net loss per share $0.74; company cited cash burn of $13.2M in operating activities.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axe Compute Inc. reported the year ended December 31, 2023 results: revenue approximately $1.8 million, net income approximately $14 million, EPS $3.48 per share.

Period: the year ended December 31, 2023
Revenue: approximately $1.8 million
Net income: approximately $14 million
EPS: $3.48 per share
Result: reported results

Exact text from the filing

results for the year ended December 31, 2023, and provided a corporate update. The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023. Q4 2023 and Recent Highlights: Reported meaningful progress with FluGen collaboration designed to bring a first-of-its-kind intranasal flu

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-001695

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.